Arena Pharmaceuticals Inc (NASDAQ:ARNA) Sellers Increased Their Shorts By 2.11%

May 16, 2018 - By Billy Entrekin

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Corporate Logo

It was reported an increase on Arena Pharmaceuticals Inc (NASDAQ:ARNA)’s shorted shares with 2.11%. It was announced in May by FINRA the 3.79M shorted shares on ARNA. The 3.71 million previous shares are up with 2.11%. With Average volume 926,000, ARNA’s previous position will take 4 days to restore. Float short on Arena Pharmaceuticals Inc is 9.68%.

The stock decreased 0.28% or $0.13 during the last trading session, touching $46.56.Arena Pharmaceuticals, Inc. has volume of 544,285 shares. Since May 16, 2017 ARNA has risen 169.40% and is uptrending. ARNA outperformed by 157.85% the S&P 500.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland.The firm is valued at $2.28 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease.Currently it has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Coverage

Total analysts of 7 have positions in Arena Pharmaceuticals (NASDAQ:ARNA) as follows: 6 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 86%. Since January 3, 2018 according to StockzIntelligence Inc Arena Pharmaceuticals has 14 analyst reports. On Tuesday, February 27 the firm has “Buy” rating by Citigroup given. On Tuesday, March 20 the firm earned “Buy” rating by Wells Fargo. On Wednesday, March 14 the firm has “Buy” rating given by Cantor Fitzgerald. On Monday, February 26 the rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, March 20 the firm earned “Buy” rating by Cantor Fitzgerald. The company rating was maintained by Cantor Fitzgerald on Wednesday, May 9. The company rating was upgraded by Wells Fargo on Wednesday, January 3. In Wednesday, January 17 report Leerink Swann maintained the stock with “Buy” rating. In Wednesday, April 18 report Cantor Fitzgerald maintained it with “Buy” rating and $6500 target. On Tuesday, March 20 the stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earned “Buy” rating by Needham.

For more Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news brought out recently go to: Seekingalpha.com, Streetinsider.com, Globenewswire.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi on Q1 2018 Results – Earnings Call Transcript” brought out on May 15, 2018, “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” on May 15, 2018, “Report: Developing Opportunities within Haemonetics, Arena Pharmaceuticals, Xperi, MoneyGram International, Boot …” with a publish date: May 15, 2018, “Arena Pharma (ARNA), Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound” and the last “My 2 Cents On The Ozanimod Saga” with publication date: May 15, 2018.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.